COPD Treatment Guideline Nov 2021 V7.1

Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure O2 Saturation Self- Address Co- Advanced Care management morbidities Planning Plan Non-pharmacological management steps Can provide important health benefits e.g.

NTS-Minutes-January-2016

This was a pharmacokinetic study with a crossover design, comparing the bioavailability of nicotine when delivered by: e-Voke 10 mg or 15 mg cartridges with Nicorette® 15 mg Inhalator or smoking a cigarette (Benson & Hedges Gold). Current data available does not evaluate the benefit of e-Voke as a stop smoking aid.

GMMMG Decision Summary March 2024 cegc and exec approved

A formulary application has been submitted to add the medicine to the GMMMG formulary for smoking cessation as a first line option alongside existing therapies. It is understood that PGDs are in development for use by smoking cessation services Cytisine is priced at £115 per 25 day course (100 tablets).

New Therapies Subgroup

This was a pharmacokinetic study with a crossover design, comparing the bioavailability of nicotine when delivered by: e-Voke 10 mg or 15 mg cartridges with Nicorette® 15 mg Inhalator or smoking a cigarette (Benson & Hedges Gold). Current data available does not evaluate the benefit of e-Voke as a stop smoking aid.

Subgroup Decision Table April 2022

schemes are This guideline covers support to stop smoking However, the following new already used in for everyone aged 12 and over, and help to recommendations on offering some areas. Areas reduce people's harm from smoking if they are voucher incentives in addition to that do not not ready to stop in one go.

November-2019-FMESG-minutes-approved

1.2 Declarations of Interest: Ahead of discussing item 4.4 (DNP Assessment: Voke inhalator) KP declared that he had undertaken some private work with Pfizer who market smoking cessation products, thus he would not participate in this agenda item.

GMMMG HCD IBD pathway – 5.0 FINAL

It is advised to avoid prescribing JAK inhibitors unless there are no suitable alternatives in patients with the following risk factors: age 65 or older, current or past long-term smoking and other risk factors for cardiovascular disease or malignancy. including light or passive smoking which carries equal risk as heavy smoking).